Bedrijfsoverzicht
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical entity focused on the discovery and development of therapeutic options for neurodegenerative diseases and endocrine conditions within the United States market. The company operates within the healthcare sector, specifically classified under the industry of drug manufacturers specializing in specialty and generic pharmaceuticals, which implies a focus on advanced therapeutic compounds rather than mass-market commodities. With a market capitalization of $1.81B and an employee count of 136, the firm maintains a relatively compact organizational structure typical of clinical-stage biotechnology enterprises. The current market cap of $1.81B, combined with the absence of reported annual revenue figures, indicates that the company's valuation is primarily driven by potential future asset value and pipeline prospects rather than established commercial earnings, positioning it as a high-potential but pre-commercial stage entity.
Financiële gezondheid
The company reports a net income of $-144,735,008 and an EBITDA of $-152,766,000, while revenue figures are listed as N/A, highlighting a cost structure where operating expenses significantly exceed any current commercial sales. The absence of revenue data alongside substantial net losses suggests that the business model is currently in a heavy investment phase where cash burn is necessary to advance clinical trials for its investigational products. Free cash flow stands at $-66,994,876, indicating a continuous outflow of capital that requires external funding sources to maintain financial flexibility and sustain ongoing research and development activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a pre-revenue stage where no commercial gross profit has been generated yet, and traditional margin analysis is not applicable to the current operational status. On the balance sheet, the company holds $316.98M in cash against a total debt obligation of $5.96M, resulting in a debt-to-equity ratio of 1.95, which presents a complex picture of high leverage relative to equity despite the substantial cash reserve. The current ratio is exceptionally high at 14.27, suggesting an abundance of current assets relative to current liabilities, though this metric is less relevant in the context of a pre-revenue company with minimal debt. Return on Equity is -61.6% and Return on Assets is -36.4%, metrics that reveal management is currently generating negative returns on invested capital, a standard characteristic for clinical-stage companies where capital is deployed to generate future value rather than current profits.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is -13.35, a negative figure that implies expected future earnings remain negative or are not projected to turn positive within the current valuation framework. The price-to-book ratio is 5.89, indicating that the market values the company at nearly six times its book value, a significant premium that reflects investor confidence in the underlying intellectual property and the potential success of the Avexitide asset rather than current tangible assets. The price-to-sales ratio is N/A and the EV/EBITDA is -9.80, suggesting that traditional valuation multiples based on sales or earnings are not currently applicable, and the market is pricing the stock based on alternative factors such as pipeline milestones or strategic partnerships. The stock has traded between a 52-week low of $3.69 and a 52-week high of $17.49, and without a specific current price to calculate the exact percentage, the range demonstrates substantial volatility inherent in clinical-stage biopharma stocks. The beta is -0.21, a negative value that indicates the stock's price movement tends to move inversely to the broader market, presenting a unique volatility profile that does not correlate with standard market indices.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated sufficient commercial revenue to calculate year-over-year growth metrics, and earnings are currently negative. Since the company does not pay a dividend, there is no dividend yield or payout ratio to evaluate, meaning the payout ratio is effectively 0.0% and all available earnings are technically unavailable for distribution to shareholders. Instead of paying dividends, the company retains its cash position to reinvest earnings directly into the discovery and development of treatments for neurodegenerative diseases and endocrine conditions. The overall growth and income profile is characterized by a complete absence of current income generation and historical growth data, with the company's trajectory dependent entirely on the successful progression of its clinical pipeline and the eventual commercialization of its investigational products.